Drug-induced neutrophilic lobular panniculitis secondary to BRAF and MEK inhibitor used for treatment of low-grade glioma and its management

Blayne Fennera School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TexasCorrespondence[email protected]

https://orcid.org/0000-0002-9865-9764

, BS

Annia Cavazosb Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TexasCorrespondence[email protected]

, MD,

Uyen Muic Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas

, MD &

Michelle Tarboxc Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas

, MD

Young TK, Gutierrez D, Criscito MC, Kim RH, Lakdawala N, Oza VS. Dabrafenib-induced neutrophilic panniculitis in a child undergoing dual BRAF-MEK inhibitor therapy for glioblastoma multiforme. Pediatr Dermatol. 2020;37(6):1185–1186. doi:10.1111/pde.14306.
PubMed Web of Science ®Google Scholar
Negulescu M, Deilhes F, Sibaud V, et al. Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect. Case Rep Dermatol. 2017;9(1):80–85. doi:10.1159/000461571.
PubMedGoogle Scholar
Choy B, Chou S, Anforth R, Fernández-Peñas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493–497. doi:10.1097/DAD.0000000000000023.
PubMed Web of Science ®Google Scholar
Sutra-Loubet C, Carlotti A, Guillemette J, Wallach D. Neutrophilic panniculitis. J Am Acad Dermatol. 2004;50(2):280–285. doi:10.1016/j.jaad.2003.10.006.
PubMed Web of Science ®Google Scholar
Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol. 2015;25(2):177–180. doi:10.1684/ejd.2014.2512.
PubMed Web of Science ®Google Scholar
Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012;148(3):357–361. doi:10.1001/archdermatol.2011.2842.
PubMedGoogle Scholar
Mössner R, Zimmer L, Berking C, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1797–1806. doi:10.1111/jdv.13039.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Drug-induced neutrophilic lobular panniculitis secondary to BRAF and MEK inhibitor used for treatment of low-grade glioma and its management

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug-induced neutrophilic lobular panniculitis secondary to BRAF and MEK inhibitor used for treatment of low-grade glioma and its management

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date